Sigallab

Our core research direction is understanding SARS-CoV-2 evolution and long term-persistence in the presence and absence of HIV co-infection, as well as the long-term consequences of Covid-19. We are particularly interested in SARS-CoV-2 variants, antibody neutralization, and cellular transmission of SARS-CoV-2. Our laboratory was the first to isolate the live Beta variant, which was made available for research worldwide. We are based in Durban, South Africa, at the epicenter of the HIV and TB epidemics. test

Alex Sigal is member of faculty at the Africa Health Research Institute Africa Health Research Institute. and associate professor at the University of KwaZulu-Natal. Alex has a PhD in Systems Biology from the Weizmann Institute and was a postdoctoral fellow with David Baltimore at the California Institute of Technology.

Publications 2021

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature.

HIV status alters disease severity and immune cell responses in beta variant SARS-CoV-2 infection wave. eLife.

T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy. PLos Pathogens.

Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave. Clin Infect Dis.

Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med.

Detection of a SARS-CoV-2 variant of concern in South Africa. Nature.

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med.

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell.

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications.

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strain. eLife.